AU2009248039B2 - Multiple myeloma treatments - Google Patents

Multiple myeloma treatments Download PDF

Info

Publication number
AU2009248039B2
AU2009248039B2 AU2009248039A AU2009248039A AU2009248039B2 AU 2009248039 B2 AU2009248039 B2 AU 2009248039B2 AU 2009248039 A AU2009248039 A AU 2009248039A AU 2009248039 A AU2009248039 A AU 2009248039A AU 2009248039 B2 AU2009248039 B2 AU 2009248039B2
Authority
AU
Australia
Prior art keywords
treatment
patient
acceptable salt
pharmaceutically acceptable
pmoo104
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009248039A
Other languages
English (en)
Other versions
AU2009248039A1 (en
Inventor
Pablo Manuel Aviles Marin
Enrique Ocio
Atanasio Pandiella
Jesus San Miguel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of AU2009248039A1 publication Critical patent/AU2009248039A1/en
Application granted granted Critical
Publication of AU2009248039B2 publication Critical patent/AU2009248039B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009248039A 2008-05-16 2009-05-18 Multiple myeloma treatments Ceased AU2009248039B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380154 2008-05-16
EP08380154.8 2008-05-16
PCT/EP2009/055978 WO2009138509A1 (en) 2008-05-16 2009-05-18 Multiple myeloma treatments

Publications (2)

Publication Number Publication Date
AU2009248039A1 AU2009248039A1 (en) 2009-11-19
AU2009248039B2 true AU2009248039B2 (en) 2014-07-31

Family

ID=40848780

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009248039A Ceased AU2009248039B2 (en) 2008-05-16 2009-05-18 Multiple myeloma treatments

Country Status (12)

Country Link
US (1) US8435992B2 (enExample)
EP (1) EP2303274A1 (enExample)
JP (1) JP2011520846A (enExample)
KR (1) KR20110028454A (enExample)
CN (1) CN102065865B (enExample)
AU (1) AU2009248039B2 (enExample)
CA (1) CA2724206A1 (enExample)
IL (1) IL209360A (enExample)
MX (1) MX2010012358A (enExample)
NZ (1) NZ589270A (enExample)
RU (1) RU2519750C2 (enExample)
WO (1) WO2009138509A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
EP2307003A2 (en) * 2008-05-16 2011-04-13 Pharma Mar S.A. Combination therapy with pm00104 and another antitumor agent
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
KR101471273B1 (ko) * 2013-01-29 2014-12-11 인제대학교 산학협력단 Ｓｏｄ２를 포함하는 보르테조밉 내성 진단용 바이오 마커 조성물 및 이를 이용한 진단 키트
KR101718800B1 (ko) 2015-01-21 2017-03-24 주식회사 디알나노 약물 및 ｓｉＲＮＡ의 공동―운반용 나노복합체 및 이의 용도
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007052076A2 (en) * 2005-10-31 2007-05-10 Pharma Mar, S.A. Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074243C (zh) * 1997-09-16 2001-11-07 林禾杰 对虾养殖方法
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US6569859B1 (en) 2000-02-22 2003-05-27 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
JP4584245B2 (ja) * 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007052076A2 (en) * 2005-10-31 2007-05-10 Pharma Mar, S.A. Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases

Also Published As

Publication number Publication date
NZ589270A (en) 2011-12-22
CA2724206A1 (en) 2009-11-19
RU2519750C2 (ru) 2014-06-20
US8435992B2 (en) 2013-05-07
JP2011520846A (ja) 2011-07-21
KR20110028454A (ko) 2011-03-18
RU2010151660A (ru) 2012-06-27
IL209360A0 (en) 2011-01-31
CN102065865A (zh) 2011-05-18
US20110076343A1 (en) 2011-03-31
IL209360A (en) 2015-10-29
AU2009248039A1 (en) 2009-11-19
EP2303274A1 (en) 2011-04-06
WO2009138509A1 (en) 2009-11-19
CN102065865B (zh) 2013-03-20
MX2010012358A (es) 2011-01-25

Similar Documents

Publication Publication Date Title
US8435992B2 (en) Multiple myeloma treatments
JP6787792B2 (ja) がんの処置のための併用治療
JP5340935B2 (ja) 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法
CN105873440B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
EP3673907A1 (en) Pharmaceutical for cancer treatment including ax1 inhibitor as an effective component
AU2003286647B2 (en) Method and composition for preventing and treating solid tumors
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
WO2018015526A1 (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
AU2023202746A1 (en) Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
KR20260018046A (ko) 이전의 면역 관문 억제제 노출 이력이 있는 대상체의 암 치료 방법
EP4719403A1 (en) Methods of treating cancer in bcl2 inhibitor naive subjects
EP1605937B1 (en) Treatment of proliferative diseases with epothilone derivatives and radiation
CA2501610C (en) Epothilone derivatives for the treatment of multiple myeloma
KR20250117425A (ko) 다발성 골수종의 치료를 위해 벨루모수딜을 투여하는 방법
WO2025090844A1 (en) Methods of treating cancer associated with reduced interleukin 1 beta expression
WO2025208000A1 (en) Methods of treating cancer in patients with altered protein expression
WO2023118062A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
EA039621B1 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
KR20190012118A (ko) 혈관차단제 및 면역 체크포인트 억제제를 포함하는 암 예방 또는 치료용 조성물
OA19180A (en) Combination of A BCL-2 inhibitor and A MCL1 inhibitor, uses and pharmaceutical compositions thereof.
WO2024220839A1 (en) Methods of treating hepatic-only metastatic uveal melanoma
NZ789582A (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired